Clinical Trial Update: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome [Phase 3]

View source ↗

Summary

Pfizer reports the completion of a long-term open-label extension study for fesoterodine (SP584) in subjects who completed the Phase 3 trial for overactive blad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Toviaz (fesoterodine fumarate)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder Syndrome | Phase 3 | Status: COMPLETED